The entity recognized a possible link with cases of thrombosis, but considered that the side effect is very rare and reiterated the safety and efficacy of the immunizer
A European Medicines Agency (EMA) maintained this Wednesday, 7, its recommendation for the use of vaccine against Covid-19 developed by the pharmaceutical company AstraZeneca in partnership with Oxford University. The entity acknowledged the existence of “a possible link” between the immunizer and problems with blood clot or low levels of blood platelets, but considered that it is a “very rare” side effect and that the balance between risks and benefits remains positive. The EMA had already taken a position on the subject on March 18, when it said it was not possible to establish a direct relationship between the vaccine and cases of thrombosis that had been reported in several countries, especially in Europe.
The opinion is similar to that of the Regulatory Agency for Medicines and Health Products of the United Kingdom, who on the last day 4 was in favor of maintaining the use of the Oxford vaccine despite having identified 30 cases of blood clots in its territory. The agency justified that the risks are “very small”, since 18.1 million people received the immunizer in the country. “The risk and benefit decision that people have when invited to receive the vaccine is simple: receiving the vaccine is by far the safest option,” said Adam Finn, a member of the Joint Vaccination and Immunization Committee. THE World Health Organization (WHO) he also spoke on the subject on March 17, when he said there was no evidence to indicate a direct link between the immunizer and blood clot problems.
Recently, Germany, Canada and the Netherlands have stated that they will not use the AstraZeneca product in adults, which appears to be the age group in which the problem is most recurrent. THE Netherlands he reported that he received five reports from women aged 25 to 65 who developed thrombosis after being vaccinated in the country, one of whom died of extensive pulmonary embolism ten days after receiving the Oxford vaccine. At Germany, there were 31 cases of thrombosis and nine fatal victims, two men aged 36 and 57 years old and seven women aged between 20 and 63 years old. O Canada, in turn, did not register any cases of blood clotting problems after the application of the AstraZeneca immunizer, but was concerned about the recurrence in other countries and asked the pharmaceutical company itself to carry out a specific study on possible side effects within the context of the study. their territory.